Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Mike Frazier was living the dream. The 2013 graduate of Frederick County’s Millbrook High School moved to Seattle in 2022 ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

These cases suggest that good seizure control after a successful ... that have contributed to suicidality. Frontal and temporal lobe networks and changes in serotonergic activity have been ...

Apr. 15, 2025 — Certain common genetic changes might make some people with focal epilepsy less responsive to seizure medications, finds a new global ... Could an Arthritis Drug Unlock Lasting ...

The new International League Against Epilepsy (ILAE) definition of epilepsy results in a higher frequency of epilepsy ...

Focal cortical dysplasia (FCD) type 2 is a congenital malformation of the cerebral cortex that is often associated with difficult-to-treat epilepsy. In the affected areas, nerve cells and their layer ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...